Table 1.
Patient characteristics, demographic features, and APVO436 exposure for safety population (N = 46).
| Diagnosis | |
|---|---|
| AML | 39 (84.8%) |
| Primary AML | 26 (56.5%) |
| Secondary (s)-AML | 9 (19.6%) |
| Treatment related (t)-AML | 4 (8.7%) |
| MDS | 7 (15.2%) |
| Age (years) | |
| Mean ± SE | 65.4 ± 2.0 |
| Median | 69 |
| Range | 18–82 |
| Sex | |
| Female | 22 (47.8%) |
| Male | 24 (52.2%) |
| Ethnic origin | |
| Caucasian, not Hispanic or Latino | 34 (73.9%) |
| Caucasian, Hispanic or Latino | 6 (13.0) |
| Black or African American | 3 (6.5%) |
| Hispanic or Latino | 1 (2.2%) |
| Asian | 2 (4.3%) |
| Prior # of chemotherapy regimens | |
| 1 | 9 (19.6%) |
| 2 | 14 (30.4%) |
| 3 | 6 (13.0%) |
| ≥4 | 16 (34.8%) |
| Range | 1–8 |
| Not reported | 1 (2.2%) |
| Mean ± SE (median) | 3.2 ± 0.3 (2.5) |
|
Number of APVO436 treatments Mean ± SE (median) |
11 ± 2 (7) |